Fund research supporting the defense advanced research projects agency (DARPA) biological technologies offices (BTO) harnessing enzymatic activity for bacterial toxins (HEALR) program

Ended Cooperative Agreement Awarded Last action

Award ID
HR00112120014
Recipient
Awarding agency
Obligated
$12,774,922

Award facts

Assistance listing
12.910 Research and Technology Development
Completion date
Originally
Place of performance
New Haven, CT 06511, USA

Award details come from USAspending.gov.

Transactions

Action Obligated Date
Amendment $799,965
Amendment The purpose of this bilateral modification is to 1 incrementally fund phase 3 option 3 clin 0004 via subclin 000403, acrn AF, by $739,079 $739,079
Amendment The purpose of this unilateral modification is to temporary change agreements officer representative AOR and incrementally fund phase 3 option 3 by $558,503 $558,503
Amendment The purpose of this unilateral modification is to exercise and incrementally fund phase 3 option 3 by $430,000.00 $430,000
Amendment The purpose of this modification is to make administrative corrections to previously issued modifications P00004 through P00007 in order to insert the correct… -$20
Amendment As authorized by exhibit a, provision 2, amendment of award and PR HR0011472085, the purpose of this unilateral modification is to increase phase II funding… $1,475,694
Amendment The purpose of this modification is to increase phase II incremental funding by $1,102,309 and update recipient facilities & administration F & a rate… $1,102,309
Amendment Phase II incremental funding is increased by $768,000 from $1,986,517 to $2,754,517, revising total funding from $6,901,392 to $7,669,392 as set for added under… $768,000
Amendment The purpose of this modification is to descope phase II effort that was spread between clins 0002 and 0003, but is reduced to only clin 0002, issue exhibit B… $1,986,517
Amendment The purpose of this modification is to 1 add incremental funding in the amount of $989,401 to fully fund the phase 1 base period clin 0001 via subclin 000105… $989,401
Amendment As authorized by PR HR0011259202, the purpose of this modification is to incrementally fund the phase I base period (clin 0001) in the amount of $904,432 via… $904,432
Amendment As authorized by PR HR0011257168, the purpose of this cooperative agreement modification is to incrementally fund phase I (clin 0001) in the amount of… $884,695
Original award $2,136,347
Show all 13

Subawards

Subrecipient Amount Awarded
SIA Partners U.s., Inc. Fully Synthetic Bifunctional Molecules that Degrade Bacterial Toxins (Phase 3, Sub 12, CRL) $87,780
University Of Sydney Subrecipient will assist with research team leadership, project management, and reporting for the DARPA HEALR award. University of Sydney will optimize MoDE… $231,196
University Of Sydney $250,000
SIA Partners U.s., Inc. LBG will provide services as detailed in the following pages, and for the Period of Performance (POP) also illustrated in Table 1 (Section 4) of the following… $82,390
SIA Partners U.s., Inc. LBG will provide services to Yale throughout the entire HEALR project Phase 2 Period (Apr2024 – Dec2024). Subawards will be awarded sequentially at a value of… $65,018
Subrecipient not on record PEPTIDREAM STATEMENT OF WORK #7 • Initial characterization of the hit peptide candidates for binding and selectivity against Pressure Test 1 target protein in… $250,000

Quick answers

Who received award HR00112120014?

HR00112120014 was awarded to Yale Univ by Defense Advanced Research Projects Agency (Department of Defense) on August 2, 2021.

How much is award HR00112120014 worth?

$12,774,922 has been obligated on HR00112120014.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login